X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
GlobeNewswire
XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndromeBreakthrough Therapy approval follows Priority..